PMID- 21312349
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20151119
IS  - 2151-4658 (Electronic)
IS  - 2151-464X (Linking)
VI  - 63
IP  - 6
DP  - 2011 Jun
TI  - Estimation of minimum clinically important difference for pain in fibromyalgia.
PG  - 821-6
LID - 10.1002/acr.20449 [doi]
AB  - OBJECTIVE: To estimate the minimum clinically important difference (MCID) for 
      several pain measures obtained from the Brief Pain Inventory (BPI) for patients 
      with fibromyalgia. METHODS: Data were pooled across 12-week treatment periods 
      from 4 randomized, double-blind, placebo-controlled studies designed to evaluate 
      the safety and efficacy of duloxetine for the treatment of fibromyalgia. Each 
      study enrolled subjects with American College of Rheumatology--defined 
      fibromyalgia who presented with moderate to severe pain. The MCIDs for the BPI 
      average pain item score and the BPI severity score (the mean of the BPI pain 
      scale values: right now, average, least, and worst) were estimated by anchoring 
      against the Patient's Global Impressions of Improvement scale. RESULTS: The 
      anchor-based MCIDs for the BPI average pain item and severity scores were 2.1 and 
      2.2 points, respectively. These MCIDs correspond to 32.3% and 34.2% reductions 
      from baseline in scores. CONCLUSION: In these analyses, the MCIDs for several 
      pain measures obtained from the BPI were similar ( approximately 2 points) and corresponded to 
      a 30-35% improvement from baseline to end point. These findings may be beneficial 
      for use in designing clinical trials in which the BPI is used to evaluate 
      improvements in pain severity.
CI  - Copyright (c) 2011 by the American College of Rheumatology.
FAU - Mease, Philip J
AU  - Mease PJ
AD  - Swedish Medical Center and University of Washington School of Medicine, Seattle, 
      USA. pmease@philipmease.com
FAU - Spaeth, Michael
AU  - Spaeth M
FAU - Clauw, Daniel J
AU  - Clauw DJ
FAU - Arnold, Lesley M
AU  - Arnold LM
FAU - Bradley, Laurence A
AU  - Bradley LA
FAU - Russell, I Jon
AU  - Russell IJ
FAU - Kajdasz, Daniel K
AU  - Kajdasz DK
FAU - Walker, Daniel J
AU  - Walker DJ
FAU - Chappell, Amy S
AU  - Chappell AS
LA  - eng
SI  - ClinicalTrials.gov/NCT00190866
SI  - ClinicalTrials.gov/NCT00233025
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Arthritis Care Res (Hoboken)
JT  - Arthritis care & research
JID - 101518086
RN  - 0 (Thiophenes)
RN  - 9044SC542W (Duloxetine Hydrochloride)
SB  - IM
MH  - Adult
MH  - Double-Blind Method
MH  - Duloxetine Hydrochloride
MH  - Female
MH  - Fibromyalgia/complications/*diagnosis/drug therapy
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pain/complications/*diagnosis/drug therapy
MH  - Pain Measurement/methods/*standards
MH  - *Severity of Illness Index
MH  - Thiophenes/therapeutic use
EDAT- 2011/02/12 06:00
MHDA- 2011/08/04 06:00
CRDT- 2011/02/12 06:00
PHST- 2011/02/12 06:00 [entrez]
PHST- 2011/02/12 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - 10.1002/acr.20449 [doi]
PST - ppublish
SO  - Arthritis Care Res (Hoboken). 2011 Jun;63(6):821-6. doi: 10.1002/acr.20449.